Therapy-related @entity3052 (t- @entity3052 ), is a severe complication of cytotoxic therapy used for primary @entity5 treatment. The outcome of these @entity1 is poor, compared to @entity1 who develop de novo @entity3052 (p- @entity3052 ). @entity2008 in t- @entity3052 are similar to those found in p- @entity3052 but present more frequent unfavorable karyotypes depending on the inducting agent. Losses of chromosome 5 or 7 are observed after alkylating agents while balanced translocations are found after topoisomerase II inhibitors. This study compared t- @entity3052 to p- @entity3052 using high resolution array CGH in order to find @entity854 ( @entity854 ) at a higher resolution than conventional cytogenetics. More CNAs were observed in 30 t- @entity3052 than in 36 p- @entity3052 : 104 CNAs were observed with 63 losses and 41 gains (mean number 3.46 per case) in t- @entity3052 , while in p- @entity3052 , 69 CNAs were observed with 32 losses and 37 gains (mean number of 1.9 per case). In @entity1778 with a previously "normal" karyotype, 18% exhibited a previously undetected @entity854 , whereas in the (few) t- @entity3052 with a normal karyotype, the rate was 50%. Several minimal critical regions (MCRs) were found in t- @entity3052 and p- @entity3052 . No common MCRs were found in the two groups. In t- @entity3052 a 40 kb deleted MCR pointed to @entity5316 on 21q22, a gene coding for a transcription factor implicated in frequent rearrangements in @entity1778 and in @entity882 . In de novo @entity3052 , a 1 Mb MCR harboring ERG and @entity21321 was observed from @entity1 with complex aCGH profiles. High resolution cytogenomics obtained by aCGH and similar techniques already published allowed us to characterize numerous non random chromosome abnormalities. This work supports the hypothesis that they can be classified into several categories: abnormalities common to all @entity3052 ; those more frequently found in t- @entity3052 and those specifically found in p- @entity3052 .

Chromosomal minimal critical regions in therapy-related XXXX appear different from those of de novo @entity1778 by high-resolution aCGH.

@entity1 :: ('9606', 'Species') :: ['patients', 'people'] @entity882 :: ('MESH:D013921', 'Disease') :: ['familial thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['AML', 'acute leukemia'] @entity854 :: ('MESH:D018376', 'Disease') :: ['copy number abnormalities', 'CNA'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['primary leukemia', 'leukemia'] @entity21321 :: ('2114', 'Gene') :: ['ETS2'] @entity2008 :: ('MESH:D002869', 'Disease') :: ['Cytogenetic abnormalities'] @entity5316 :: ('861', 'Gene') :: ['RUNX1']
@entity1778 :: (MESH:D007938,Disease) :: ['leukemia']
